

Evaluation of Dexamethasone Premedication Prescribing for Docetaxel

Kianna Boc, PharmD Candidate, **Danielle Gundrum**, PharmD, BCOP, **Kelsey Brown**, PharmD, Allison Snoke, PharmD, BCOP, **Megan Mullalley**, PharmD, BCOP, BCPS*

INTRODUCTION:

- Docetaxel is an antineoplastic agent that is generally well tolerated
- It is recommended to premedicate with corticosteroids such as dexamethasone to reduce the incidence and severity of adverse reactions:
 - Fluid retention
 - Hypersensitivity reactions

OBJECTIVE:

- Evaluate whether Intermountain Healthcare's (IHC) prescribing patterns follow docetaxel's package insert dexamethasone premedication recommendation

METHODS:

- Retrospective chart review, docetaxel doses prescribed in any outpatient regimen between February 1, 2022, to April 30, 2022
- Data collection included Utah-based treatment facility locations, indication, first docetaxel treatment date, and appropriate docetaxel premedication prescription
- Inclusion criteria: Any docetaxel regimen prescribed at a Utah-based IHC outpatient facility. First treatments initiated before February 2022 were also included.
- Exclusions criteria: Any docetaxel regimens initiated after April 2022


RESULTS:

- 77 docetaxel regimens were recorded during this timeline
 - 58.44% (45 out of 77) regimens were prescribed dexamethasone prior to their docetaxel treatment
 - 38.96% (30 out of 77) regimens were not prescribed dexamethasone prior to their docetaxel treatment
 - 2 regimens were prescribed dexamethasone during the middle of their treatment cycle
- Treatment indications:
 - Breast (46)
 - Prostate (12)
 - Non-Small Cell Lung Cancer (NSLCL) (10)
 - Other (10)**
- IHC facility locations most likely prescribing dexamethasone:
 - Intermountain Medical Center
 - St. George
 - Logan
 - Cedar City



Most Docetaxel Regimens were

Appropriately Prescribed Dexamethasone as Premedication per Recommendation

Regimens Receiving Dexamethasone Prior to Docetaxel



Dexamethasone Prescribed Per IHC Location



CONCLUSION:

- 58.44% of docetaxel regimens were appropriately prescribed dexamethasone as premedication for docetaxel as per the manufacturer's recommendation
- Further investigation into the prevalence of docetaxel adverse events and providing education about the importance of anti-cancer therapy premedication are future considerations for this project

**Other treatment indications:

- Ovarian
- Gastroesophageal
- Osteosarcoma
- Uterine Leiomyosarcoma
- Spindle Cell
- Small Cell Lung Cancer

*None of the authors had anything to disclose